Compare · DFTX vs XXII
DFTX vs XXII
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and 22nd Century Group Inc. (XXII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and XXII operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.02B, about 18.1x XXII ($332.0M).
- DFTX has been more active in the news (15 items in the past 4 weeks vs 7 for XXII).
- DFTX has more recent analyst coverage (7 ratings vs 4 for XXII).
- Company
- Definium Therapeutics Inc.
- 22nd Century Group Inc.
- Price
- -
- -
- Market cap
- $6.02B
- $332.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- AMEX
- IPO
- News (4w)
- 15
- 7
- Recent ratings
- 7
- 4
22nd Century Group Inc.
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Latest XXII
- 22nd Century Group to Participate in the HC Wainwright Conference on September 15, 2026
- SEC Form S-8 filed by 22nd Century Group Inc.
- SEC Form 10-Q filed by 22nd Century Group Inc.
- 22nd Century Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 22nd Century Group Reports Second Quarter 2026 Financial Results
- 22nd Century Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- 22nd Century Group to Announce Second Quarter 2026 Results on August 13, 2026
- 22nd Century Group (Nasdaq: XXII) Appoints Katherine Rouse-Bailey as Vice President of Marketing
- SEC Form 8-K filed by 22nd Century Group Inc.
- SEC Form 424B3 filed by 22nd Century Group Inc.